1. Lefebvre S. et al. Identification and characterization of a spinal muscular atrophy-determining gene // Cell. Elsevier, 1995. Vol. 80, № 1. P. 155–165.
2. Anderton R.S. et al. Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein // Mol. Neurobiol. 2013. Vol. 47, № 2. P. 821–832.
3. Prior T.W. et al. A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene // Am. J. Hum. Genet. Elsevier, 2009. Vol. 85, № 3. P. 408–413.
4. Wirth B. et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number // Hum. Genet. 2006. Vol. 119, № 4. P. 422–428.
5. Vitali T. et al. Detection of the Survival Motor Neuron (SMN) Genes by FISH: Further Evidence for a Role for SMN2 in the Modulation of Disease Severity in SMA Patients // Hum. Mol. Genet. 1999. Vol. 8, № 13. P. 2525–2532.
6. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated 2020 Dec 3]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1352/.
7. Kashima T., Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy // Nat. Genet. 2003. Vol. 34, № 4. P. 460–463.
8. Arnold E.S., Fischbeck K.H. Spinal muscular atrophy // Handb. Clin. Neurol. Neurogenetics Branch, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States., 2018. Vol. 148. P. 591–601.
9. Lipnick S.L. et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims // PLoS One. Public Library of Science, 2019. Vol. 14, № 3. P. e0213680–e0213680.
10. Mailman M.D. et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2 // Genet. Med. 2002. Vol. 4, № 1. P. 20–26.
11. Calucho M. et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases // Neuromuscul. Disord. Elsevier, 2018. Vol. 28, № 3. P. 208–215.
12. Nance J.R. Spinal Muscular Atrophy // Contin. (Minneap Minn). 2020. Vol. 26, № 5. P. 1348–1368.
13. Lusakowska A. et al. Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy // Orphanet J. Rare Dis. 2021. Vol. 16, № 1. P. 150.
14. Sugarman E.A. et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens // Eur. J. Hum. Genet. 2012. Vol. 20, № 1. P. 27–32.
15. König K. et al. De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany // Orphanet J. Rare Dis. 2019. Vol. 14, № 1. P. 152.
16. Verhaart I.E.C. et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review // Orphanet J. Rare Dis. 2017. Vol. 12, № 1. P. 124.
17. Zabnenkova V. et al. Spinal muscular atrophy carrier frequency in Russian Federation. 2016.
18. Wijngaarde C.A. et al. Natural history of lung function in spinal muscular atrophy // Orphanet J. Rare Dis. 2020. Vol. 15, № 1. P. 88.
19. Mercuri E. et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care // Neuromuscul. Disord. Elsevier, 2018. Vol. 28, № 2. P. 103–115.
20. Bürglen L. et al. Survival motor neuron gene deletion in the arthrogryposis multiplex congenita-spinal muscular atrophy association // J. Clin. Invest. 1996. Vol. 98, № 5. P. 1130–1132.
21. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype // Eur. J. Paediatr. Neurol. 1999. Vol. 3, № 2. P. 49–51.
22. Grotto S. et al. Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients // J. Neuromuscul. Dis. IOS Press, 2016. Vol. 3. P. 487–495.